FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242043766> ?p ?o ?g. }

• W4242043766 endingPage "x26" @default.
• W4242043766 startingPage "x26" @default.
• W4242043766 abstract "Background: For pts with unresectable HCC, systemic therapy options are limited. Sorafenib and lenvatinib are approved in the US and Europe for HCC treatment. For pts who progress on sorafenib, regorafenib and nivolumab are approved as second-line therapy. Cemiplimab (REGN2810) has demonstrated encouraging efficacy and safety profile in a Phase 1 dose escalation study in pts with advanced malignancies (NCT02383212). We present results of the Phase 1 HCC EC. Methods: HCC pts who are not candidates for surgery and had progressed on, could not tolerate, or refused first-line systemic therapy received cemiplimab 3 mg/kg Q2W IV for up to 48 weeks. The objectives were to evaluate the safety and tolerability (primary) and antitumour activity (secondary) of cemiplimab. Results: As of 1 Sept 2017, 26 pts were enrolled (25 M/1 F; median age: 65 [range: 40–78] years; ≥1 prior systemic therapy: 24 pts [92.3%]; ECOG PS: 1 in 19 pts [73.1%], 0 in 6 [23.1%], and missing in 1). Median duration of follow-up was 7.2 (range: 1.8–15.5) months. By investigator assessment, 5 pts (19.2%) had partial response, 14 (53.8%) had stable disease, 6 (23.1%) had progressive disease and 1 was not evaluable. Median progression-free survival was 3.7 months (95% CI: 2.3–9.1). Five pts (19.2%) completed the planned 48-week treatment, and 21 (80.8%) discontinued prematurely, primarily due to disease progression (65.4%). Three of the 5 pts who completed planned treatment remain without disease progression at the last response assessment. The most common treatment-emergent adverse events (TEAEs) of any grade were fatigue (26.9%), decreased appetite, increased aspartate aminotransferase (AST), abdominal pain, pruritus, and dyspnoea (each 23.1%). Grade ≥3 TEAEs occurring in ≥ 2 pts were hyponatraemia (3 pts), autoimmune hepatitis (2 pts) and increased AST (2 pts). Two pts (7.7%) had a TEAE resulting in death: 1 with pulmonary embolism that was considered unrelated to treatment and another with hepatic failure considered possibly related to treatment. Conclusions: Cemiplimab demonstrated evidence of antitumour activity in pts with advanced or metastatic HCC. The safety profile is comparable with that of other anti-PD-1 inhibitors. Editorial acknowledgement: Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication Practice guidelines. Clinical trial identification: NCT02383212. Legal entity responsible for the study: Regeneron Pharmaceutical Inc. and Sanofi. Funding: Regeneron Pharmaceutical Inc. and Sanofi. Disclosure: G.J. Weiss: Personal fees and ownership interest: Circulogene; Ownership interest: Angiex; Personal fees: Paradigm, Igynta, IDEA Pharma, GLG Council, Guidepoint Global; Travel/lodging fees: Cambridge Health tech Institute, Tesaro; Patent PCT/US2011/020612 issued. G. Falchook: Funding for trial for submitted work. N.S. Yee: Research, travel, accommodation and expenses: Daiichi Sankyo, Foundation Medicine, Caris Life Sciences. S. Shahda: Advisory board fees: Ipsen, Bayer; Research grants: Incyte, Apexian. M. Crittenden: Research funding: Jounce, Nanobiotix. R. Al-Rajabi: Grants: Regeneron Pharmaceuticals Inc., during the conduct of the study. E. Stankevich: Shareholder and employee: Regeneron Pharmaceuticals, Inc.; Shareholder: Celgene, Bristol-Myers Squibb, Merck. M. Feng: Shareholder and employee of Regeneron Pharmaceuticals, Inc.; Shareholder: Bayer. J. Li, M. Mathias, G. Kroog: Shareholder and employee: Regeneron Pharmaceuticals, Inc. I. Lowy: Shareholder and employee, fees for travel and accommodation expenses, leadership: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder, employee, patents, royalties, other intellectual property: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest." @default.
• W4242043766 created "2022-05-12" @default.
• W4242043766 creator A5001858951 @default.
• W4242043766 creator A5008375736 @default.
• W4242043766 creator A5009690244 @default.
• W4242043766 creator A5017964678 @default.
• W4242043766 creator A5021453899 @default.
• W4242043766 creator A5026335885 @default.
• W4242043766 creator A5031475492 @default.
• W4242043766 creator A5038238143 @default.
• W4242043766 creator A5043220508 @default.
• W4242043766 creator A5048709555 @default.
• W4242043766 creator A5063627366 @default.
• W4242043766 creator A5069482220 @default.
• W4242043766 creator A5069777765 @default.
• W4242043766 creator A5070409072 @default.
• W4242043766 creator A5071551404 @default.
• W4242043766 creator A5074945035 @default.
• W4242043766 creator A5079422406 @default.
• W4242043766 creator A5080669646 @default.
• W4242043766 creator A5091389881 @default.
• W4242043766 creator A5091886021 @default.
• W4242043766 date "2018-12-01" @default.
• W4242043766 modified "2023-10-06" @default.
• W4242043766 title "Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study" @default.
• W4242043766 doi "https://doi.org/10.1093/annonc/mdy487.004" @default.
• W4242043766 hasPublicationYear "2018" @default.
• W4242043766 type Work @default.
• W4242043766 citedByCount "4" @default.
• W4242043766 countsByYear W42420437662020 @default.
• W4242043766 countsByYear W42420437662021 @default.
• W4242043766 countsByYear W42420437662022 @default.
• W4242043766 countsByYear W42420437662023 @default.
• W4242043766 crossrefType "journal-article" @default.
• W4242043766 hasAuthorship W4242043766A5001858951 @default.
• W4242043766 hasAuthorship W4242043766A5008375736 @default.
• W4242043766 hasAuthorship W4242043766A5009690244 @default.
• W4242043766 hasAuthorship W4242043766A5017964678 @default.
• W4242043766 hasAuthorship W4242043766A5021453899 @default.
• W4242043766 hasAuthorship W4242043766A5026335885 @default.
• W4242043766 hasAuthorship W4242043766A5031475492 @default.
• W4242043766 hasAuthorship W4242043766A5038238143 @default.
• W4242043766 hasAuthorship W4242043766A5043220508 @default.
• W4242043766 hasAuthorship W4242043766A5048709555 @default.
• W4242043766 hasAuthorship W4242043766A5063627366 @default.
• W4242043766 hasAuthorship W4242043766A5069482220 @default.
• W4242043766 hasAuthorship W4242043766A5069777765 @default.
• W4242043766 hasAuthorship W4242043766A5070409072 @default.
• W4242043766 hasAuthorship W4242043766A5071551404 @default.
• W4242043766 hasAuthorship W4242043766A5074945035 @default.
• W4242043766 hasAuthorship W4242043766A5079422406 @default.
• W4242043766 hasAuthorship W4242043766A5080669646 @default.
• W4242043766 hasAuthorship W4242043766A5091389881 @default.
• W4242043766 hasAuthorship W4242043766A5091886021 @default.
• W4242043766 hasBestOaLocation W42420437661 @default.
• W4242043766 hasConcept C121608353 @default.
• W4242043766 hasConcept C126322002 @default.
• W4242043766 hasConcept C141071460 @default.
• W4242043766 hasConcept C143998085 @default.
• W4242043766 hasConcept C197934379 @default.
• W4242043766 hasConcept C2775832928 @default.
• W4242043766 hasConcept C2776248978 @default.
• W4242043766 hasConcept C2776264508 @default.
• W4242043766 hasConcept C2777701055 @default.
• W4242043766 hasConcept C2778019345 @default.
• W4242043766 hasConcept C2778375690 @default.
• W4242043766 hasConcept C2778695046 @default.
• W4242043766 hasConcept C2778822529 @default.
• W4242043766 hasConcept C2779134260 @default.
• W4242043766 hasConcept C2780030458 @default.
• W4242043766 hasConcept C31760486 @default.
• W4242043766 hasConcept C526805850 @default.
• W4242043766 hasConcept C535046627 @default.
• W4242043766 hasConcept C71924100 @default.
• W4242043766 hasConcept C72563966 @default.
• W4242043766 hasConcept C90924648 @default.
• W4242043766 hasConceptScore W4242043766C121608353 @default.
• W4242043766 hasConceptScore W4242043766C126322002 @default.
• W4242043766 hasConceptScore W4242043766C141071460 @default.
• W4242043766 hasConceptScore W4242043766C143998085 @default.
• W4242043766 hasConceptScore W4242043766C197934379 @default.
• W4242043766 hasConceptScore W4242043766C2775832928 @default.
• W4242043766 hasConceptScore W4242043766C2776248978 @default.
• W4242043766 hasConceptScore W4242043766C2776264508 @default.
• W4242043766 hasConceptScore W4242043766C2777701055 @default.
• W4242043766 hasConceptScore W4242043766C2778019345 @default.
• W4242043766 hasConceptScore W4242043766C2778375690 @default.
• W4242043766 hasConceptScore W4242043766C2778695046 @default.
• W4242043766 hasConceptScore W4242043766C2778822529 @default.
• W4242043766 hasConceptScore W4242043766C2779134260 @default.
• W4242043766 hasConceptScore W4242043766C2780030458 @default.
• W4242043766 hasConceptScore W4242043766C31760486 @default.
• W4242043766 hasConceptScore W4242043766C526805850 @default.
• W4242043766 hasConceptScore W4242043766C535046627 @default.
• W4242043766 hasConceptScore W4242043766C71924100 @default.
• W4242043766 hasConceptScore W4242043766C72563966 @default.
• W4242043766 hasConceptScore W4242043766C90924648 @default.
• W4242043766 hasLocation W42420437661 @default.

• next